Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials for Cancer in United States

7251 results

Sort By:

Daratumumab in STK11 Mutated NSCLC

Study ID: NCT05807048
Start Date: 2023-06-01
End Date: 2026-12
Study Type

Interventional

Study Phase

Phase2

No. of Participants

14

Intervention / Treatment

Daratumumab and Hyaluronidase-fihj

Pre-Intervention Medication

Post-Intervention Medication

Sponsor

NYU Langone Health

Source: clinicaltrials.gov

Share:
Add to list

Survivorship Care for Women Living With Ovarian Cancer: (POSTCARE-O)

Study ID: NCT05752448
Start Date: 2023-10-01
End Date: 2027-04-15
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

120

Intervention / Treatment

POSTCare Survivorship transition process

Sponsor

Baylor College of Medicine

Source: clinicaltrials.gov

Share:
Add to list

A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

Study ID: NCT05028348
Start Date: 2022-04-19
End Date: 2029-03
Study Type

Interventional

Study Phase

Phase3

No. of Participants

222

Intervention / Treatment

Selinexor

Elotuzumab

Pomalidomide

Dexamethasone Oral

Sponsor

The European Myeloma Network Foundation

Source: clinicaltrials.gov

Share:
Add to list

A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma

Study ID: NCT06057948
Start Date: 2023-09-21
End Date: 2026-03-21
Study Type

Interventional

Study Phase

Phase2

No. of Participants

94

Intervention / Treatment

OPT-821 (QS-21)

oral β-glucan

Sponsor

Memorial Sloan Kettering Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program

Study ID: NCT05008848
Start Date: 2022-04-01
End Date: 2028-08-26
Study Type

Interventional

Study Phase

Phase3

No. of Participants

600

Intervention / Treatment

Smoking Cessation Intervention

Health Promotion and Education

Informational Intervention

Administration questionnaire

Sponsor

Alliance for Clinical Trials in Oncology

Source: clinicaltrials.gov

Share:
Add to list

Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant

Study ID: NCT04876248
Start Date: 2024-08-19
End Date: 2026-09-01
Study Type

Interventional

Study Phase

Phase2

No. of Participants

20

Intervention / Treatment

Mafodotin Belantamab

Lenalidomide

Sponsor

Roswell Park Cancer Institute

Source: clinicaltrials.gov

Share:
Add to list

Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurrent Colorectal Cancer

Study ID: NCT06307548
Start Date: 2024-07-30
End Date: 2027-06-01
Study Type

Interventional

Study Phase

Phase2

No. of Participants

21

Intervention / Treatment

Aminolevulinic acid

Biospecimen Collection

Computed Tomography

Fluorescence-Guided Surgery

Magnetic Resonance Imaging

Photodynamic Therapy

Surgical Procedure

Sponsor

Roswell Park Cancer Institute

Source: clinicaltrials.gov

Share:
Add to list

rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

Study ID: NCT04943848
Start Date: 2022-01-10
End Date: 2025-12
Study Type

Interventional

Study Phase

Phase1

No. of Participants

36

Intervention / Treatment

rHSC-DIPGVax

The supportilimab

Zalifrelimab

Sponsor

Ann & Robert H Lurie Children's Hospital of Chicago

Source: clinicaltrials.gov

Share:
Add to list

Pyrimethamine as an Inhibitor of NRF2 in HPV-unrelated Locally Advanced Head and Neck Squamous Cell Carcinoma

Study ID: NCT05678348
Start Date: 2023-08-03
End Date: 2026-04-15
Study Type

Interventional

Study Phase

Early_phase1

No. of Participants

22

Intervention / Treatment

Pyrimethamine

Sponsor

Washington University School of Medicine

Source: clinicaltrials.gov

Share:
Add to list

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

Study ID: NCT05669430
Start Date: 2023-03-23
End Date: 2027-09-05
Study Type

Interventional

Study Phase

Phase2

No. of Participants

365

Intervention / Treatment

GV20-0251

GV20-0251

GV20-0251 and Pembrolizumab [KEYTRUDA®]

GV20-0251 and Pembrolizumab [KEYTRUDA®]

Sponsor

GV20 Therapeutics

Source: clinicaltrials.gov

Share:
Add to list